



Cigna

Oncology Medication and Code List

*****Please note: This list constantly evolves as a result of new drugs coming to market (and being approved by the U.S. Food and Drug Administration) and the Centers for Medicare & Medicaid Services issuing Healthcare Common Procedure Coding System (HCPCS) code changes. Please contact EviCore healthcare, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed*****

The integrated medical and pharmacy oncology management program supports both the customer and provider by incorporating a National Comprehensive Cancer Network® reviewed ‘regimen of care’ for the entire course of medication treatment.

- *Providers should submit prior authorization requests to Cigna for drugs that will be used for non-oncology indications.*
- *Oral medications are eligible for coverage under your Cigna patient’s pharmacy benefit.*
- *Coverage for specialty injectables is determined by your patient’s benefit plan. When benefits allow, certain injectables may be covered under your patient’s pharmacy benefit .*
- *Under many benefit plans, medically necessary services must be rendered in the least intensive setting that is appropriate for the delivery of the services and supplies. Where applicable, your patient’s benefit plan may compare the cost-effectiveness of alternative services, settings, or supplies when determining the least intensive setting.*
- *Certain specialty medical injectables must be dispensed and their claims must be submitted by a specialty pharmacy with which Cigna has a reimbursement arrangement, unless otherwise authorized by Cigna. When applicable, Cigna may grant an exception to reimburse a one-time, or single, administration billed by a facility when a customer needs access to the injectable before it can be obtained from a specialty pharmacy with which Cigna has a reimbursement arrangement.*

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
5-Fluorouracil- Injection	5FU, Adrucil	J9190	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
5-Fluorouracil- Injection	5FU, Favlyxa	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	New 505b2 drug for 5FU, Adrucil, effective: 07/01/26
Abemaciclib - oral	Verzenio	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Abiraterone Acetate - oral	Yonsa (not interchangeable with Zytiga)	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Abiraterone Acetate - oral	Zytiga (not interchangeable with Yonsa)	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Acalabrutinib - oral	Calquence	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Adagrasib - oral	Krazati	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ado-Trastuzumab Emtansine	Kadcyla	J9354	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Afatinib - oral	Gilotrif	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Aldesleukin	Proleukin, Interleukin-2	J9015	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Alectinib - oral	Alecensa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
All-trans Retinoic Acid - oral	Vesanoid, ATRA, Tretinoin	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Alpelisib - oral	Piqray	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Amivantamab and hyaluronidase-lpuj	Rybrevent Faspro	J9062	Medical Oncology - CHEMO	Primary	INJECTABLE	Y - 07/01/26	New subcutaneous primary chemotherapy for Rybrevent, effective: 7/1/26 New permanent code: J9062 will replace NOC Codes: C9399 and J9999, effective: 07/01/26
Amivantamab-vmjw	Rybrevent	J9061	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Anakinra	Kineret	J3590	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Apalutamide - oral	Erleada	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Aprepitant - oral	Emend	J8501	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y	
Arsenic Trioxide	Trisenox	J9017	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Asciminib - oral	Scemblix	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Asparaginase erwinia chrysanthemi (recombinant)-rywn	Rylaze	J9021	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Atezolizumab	Tecentriq	J9022	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Atezolizumab and Hyaluronidase-tqjs	Tecentriq Hybreza	J9024	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Avapritinib - oral	Ayvakit	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Avelumab	Bavencio	J9023	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Avutometinib and Defactinib - Oral	Avmapki Fakzynja Co-pack	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Axitinib - oral	Inlyta	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Azacitidine	Vidaza	J9025	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Azacitidine - oral	Onureg	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	Medicare Part B
Belantamab mafodotin-blmf	Blenrep	J9053	Medical Oncology - CHEMO	Primary	INJECTABLE	Y - 07/01/26	New permanent HCPC Code: J9053 will replace NOC Codes: C9399 and J9999, effective: 07/01/26
Belinostat	Beleodaq	J9032	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Belzutifan - oral	Welireg	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Bendamustine (Vivimusta)	Vivimusta	J9056	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bendamustine HCL	Belrapzo	J9036	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bendamustine HCL	Bendeka	J9034	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bendamustine HCL	Treanda	J9033	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bevacizumab	Avastin	J9035	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bevacizumab (Radiation Necrosis)	Avastin	J9035	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	Supportive use of Avastin to treat Radiation Induced Necrosis of the CNS
Bevacizumab-adcd	Vegzelma	Q5129	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Bevacizumab-adcd	Vegzelma	Q5129	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	Supportive use of Vegzelma to treat Radiation Induced Necrosis of the CNS
Bevacizumab-awwb	Mvasi	Q5107	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Bevacizumab-awwb (Radiation Necrosis)	Mvasi	Q5107	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	Supportive use of Mvasi to treat Radiation Induced Necrosis of the CNS
Bevacizumab-bvzr	Zirabev	Q5118	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	Supportive use of Zirabev to treat Radiation Induced Necrosis of the CNS
Bevacizumab-bvzr	Zirabev	Q5118	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Bevacizumab-maly	Alymsys	Q5126	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Bevacizumab-maly (Radiation Necrosis)	Alymsys	Q5126	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	Supportive use of Alymsys to treat Radiation Induced Necrosis of the CNS
Bevacizumab-nwgd	Jobevne	Q5160	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Bevacizumab-nwgd	Jobevne	Q5160	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	Supportive use of Alymsys to treat Radiation Induced Necrosis of the CNS
Bevacizumab-tjnj	Avzivi	C9399	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Bevacizumab-tjnj	Avzivi	C9399	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	Supportive use of Avzivi to treat Radiation Induced Necrosis of the CNS.
Bevacizumab-tjnj	Avzivi	J9999	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Bevacizumab-tjnj	Avzivi	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	Supportive use of Avzivi to treat Radiation Induced Necrosis of the CNS.
Bexarotene - oral	Targretin	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Binimetinib - oral	Mektovi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Bleomycin	Blenoxane	J9040	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Blinatumomab	Blincyto	J9039	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bortezomib	Velcade	J9041	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bortezomib (boruzu)	Boruzu	J9054	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bortezomib (hospira)	Bortezomib (hospira)	J9049	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bortezomib (maia)	Bortezomib (maia)	J9051	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Bosutinib - oral	Bosulif	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Brentuximab Vedotin	Adcetris	J9042	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Brigatinib - oral	Alunbrig	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Burosumab-twza	Crysvita	J0584	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Cabazitaxel	Jevtana	J9043	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Cabozantinib - oral	Cabometyx	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Cabozantinib - oral	Cometriq	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Calaspargase pegol-mknl	Asparlas	J9118	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Capecitabine - oral	Xeloda (50 mg)	J8522	Medical Oncology - CHEMO	Primary	ORAL	Y	Medicare Part B
Capivasertib - oral	Truqap	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Capmatinib - oral	Tabrecta	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Carboplatin	Paraplatin	J9045	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Carboplatin (avyxa)	Kyxata	J9278	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Carfilzomib	Kyprolis	J9047	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Carmustine (accord)	Carmustine (accord)	J9052	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Cemiplimab-rwlc	Libtayo	J9119	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Ceritinib - oral	Zykadia	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Cetuximab	Erbix	J9055	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Cisplatin	Platinol	J9060	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Cladribine	Leustatin	J9065	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Clofarabine	Clolar	J9027	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Cobimetinib - oral	Cotellic	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Cosibelimab-ipdl	Unloxcyt	J9275	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Crizotinib - oral	Xalkori	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Cyclophosphamide - oral	Cytoxan	J8530	Medical Oncology - CHEMO	Primary	ORAL	Y	Medicare Part B
Cytarabine	Ara-C	J9100	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Dabrafenib - oral	Tafinlar	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Dacarbazine	DTIC-Dome	J9130	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Dacomitinib - oral	Vizimpro	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Dactinomycin	Cosmegen, Actinomycin	J9120	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Daratumumab	Darzalex	J9145	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Daratumumab and hyaluronidase-fihj	Darzalex Faspro	J9144	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Darbepoetin alfa	Aranesp	J0881	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Darolutamide - oral	Nubeqa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Dasatinib - oral	Phyrago	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Dasatinib - oral	Sprycel	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Datopotamab deruxtecan-dlnk	Datroway	J9011	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Daunorubicin	Cerubidine	J9150	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Decitabine	Dacogen	J0894	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Decitabine (sun pharma)	Decitabine (sun pharma)	J0893	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Decitabine and cedazuridine - oral	Inqovi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Degarelix	Firmagon	J9155	Medical Oncology - CHEMO	Primary - LHRH	INJECTABLE	Y	
Denileukin Diftitox-cxdl	Lymphir	J9161	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Denosumab	Xgeva	J0897	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	Primary chemotherapy drug for the use of Xgeva to treat Giant Cell Tumor.
Denosumab	Xgeva, Prolia	J0897	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Denosumab-adet	Ponlinsi	C9399	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Denosumab-adet	Ponlinsi	J3490	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Denosumab-adet	Ponlimsi	J3590	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Denosumab-adet	Ponlimsi	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Denosumab-bbdz	Wyost	Q5136	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	Primary chemotherapy drug for the use of Wyost, to treat Giant Cell Tumor.
Denosumab-bbdz	Wyost, Jubbonti	Q5136	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Denosumab-bmwo	Osenvelt	Q5157	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	Primary chemotherapy drug for the use of Wyost, to treat Giant Cell Tumor.
Denosumab-bmwo	Osenvelt, Stoboclo	Q5157	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Denosumab-bnht	Bomynta	Q5158	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	Primary chemotherapy drug for the use of Wyost, to treat Giant Cell Tumor.
Denosumab-bnht	Bomynta, Conexence	Q5158	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Denosumab-desu	Jubereq	Q5166	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y - 07/01/26	Primary chemotherapy drug for the use of Wyost, to treat Giant Cell Tumor. New permanent code: Q5166 will replace NOC Codes: C9399 and J3590, effective: 07/01/26
Denosumab-desu	Jubereq, Osvyrti	Q5166	Medical Oncology - SPORT	Supportive	INJECTABLE	Y - 07/01/26	New permanent code: Q5166 will replace NOC Codes: C9399 and J3590, effective: 07/01/26
Denosumab-kyqq	Aukelso	Q5161	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Denosumab-kyqq	Aukelso, Bosaya	Q5161	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Denosumab-mobz	Oziltus	Q5165	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y - 07/01/26	New denosumab biosimilar, effective: 01/15/26 New permanent HCPC Code: Q5165 will replace NOC Codes: C9399 and J3590, effective: 07/01/26
Denosumab-mobz	Oziltus, Boncresa	Q5165	Medical Oncology - SPORT	Supportive	INJECTABLE	Y - 07/01/26	New denosumab biosimilar, effective: 01/15/26 New permanent HCPC Code: Q5165 will replace NOC Codes: C9399 and J3590, effective: 07/01/26
Denosumab-nxxp	Bilprevda	Q5162	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Denosumab-nxxp	Bilprevda, Bildyos	Q5162	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Denosumab-qbde	Xtrenbo	Q5167	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y - 07/01/26	New denosumab biosimilar, effective: 09/26/25 New permanent HCPC Code: Q5167 will replace NOC Codes: C9399 and J3590, effective: 07/1/26
Denosumab-qbde	Xtrenbo, Enoby	Q5167	Medical Oncology - SPORT	Supportive	INJECTABLE	Y - 07/01/26	New denosumab biosimilar, effective: 09/26/25 New permanent HCPC Code: Q5167 will replace NOC Codes: C9399 and J3590, effective: 07/1/26
Dinutuximab	Unituxin	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Dinutuximab	Unituxin	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Docetaxel	Taxotere	J9171	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Docetaxel (beizray)	Beizray	J9174	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Docetaxel (docivyx)	Docivyx	J9172	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Docetaxel (hospira)	Hospira	J9232	Medical Oncology - CHEMO	Primary	INJECTABLE	Y - 07/01/26	New HCPCS Doxetaxel (Hospira) (a 5052b drug) effective 7/1/26.
Dolasetron Mesylate - oral	Anzemet	J8597	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y	
Dordaviprone - oral	Modeyso	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Dostarlimab-gxly	Jemperli	J9272	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Doxorubicin HCL	Adriamycin	J9000	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Doxorubicin HCL (liposomal)	Doxil, Doxorubicin HCL (Liposomal) not otherwise specified	Q2050	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Dronabinol - oral	Marinol (Brand Only for Cigna)	Q0167	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y	
Dronabinol - oral	Syndros (Brand Only for Cigna)	Q0155	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y	
Durvalumab	Imfinzi	J9173	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Duvelisib - oral	Copiktra	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Efbemalenograstim alfa-vuxw	Ryzneuta	J9361	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Eflapegrastim-xnst	Rolvedon	J1449	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Eflornithine - oral	Iwifin	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Elacestrant - oral	Orserdu	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Elotuzumab	Empliciti	J9176	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Elranatamab-bcmm	Elrexio	J1323	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Enasidenib - oral	IDHIFA	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Encorafenib - oral	Braftovi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Enfortumab vedotin-efv	Padcev	J9177	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Ensartinib - oral	Ensacove	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Entrectinib - oral	Rozlytrek	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Enzalutamide - oral	Xtandi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Epcoritamab-bysp	Epkinly	J9321	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Epirubicin	Ellence	J9178	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Epoetin alfa	Epogen, Procrit	J0885	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Epoetin alfa-epbx	Retacrit	Q5106	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Erdafitinib-oral	Balversa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Eribulin mesylate	Halaven	J9179	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Erlotinib - oral	Tarceva	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Etoposide - inj	Avopef	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	505b2 drug for Etoposide; effective 7/1/26
Etoposide - inj	Toposar, VePesid, Etopophos	J9181	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Everolimus - oral	Afinitor	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Fam-trastuzumab deruxtecan-nxki	Enhertu	J9358	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Fedratinib - oral	Inrebic	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Filgrastim	Neupogen	J1442	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Filgrastim-ayow	Releuko	Q5125	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Filgrastim-laha	Filkri	C9399	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Filgrastim-laha	Filkri	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Filgrastim-txid	Nypozi	Q5148	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Floxuridine	FUDR	J9200	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Fludarabine Phosphate	Fludara, Oforta	J9185	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Fruzoquinib - oral	Fruzaqla	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Fulvestrant	Faslodex	J9395	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Fulvestrant (fresenius kabi)	Fulvestrant (fresenius kabi)	J9394	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Futibatinib - oral	Lytgobi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Gefitinib - oral	Iressa	J8565	Medical Oncology - CHEMO	Primary	ORAL	Y	
Gemcitabine	Gemzar	J9201	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Gemcitabine (avyxa)	Avgemsi	J9184	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Gemcitabine Hydrochloride (accord)	Gemcitabine Hydrochloride (accord)	J9196	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Gemcitabine Intravesical	Inlexzo	J9183	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Gemtuzumab Ozogamicin	Mylotarg	J9203	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Gilteritinib - oral	Xospata	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Glasdegib - oral	Daurismo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Glofitamab-gxbl	Columvi	J9286	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Goserelin acetate implant	Zoladex	J9202	Medical Oncology - CHEMO	Primary - LHRH	INJECTABLE	Y	
Granisetron - transdermal	Sancuso	J3490	Medical Oncology - SPORT	Supportive - Antiemetic	TRANSDERMAL	Y	
Ibrutinib - oral	Imbruvica	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Idarubicin HCL - inj	Idamycin	J9211	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Idelalisib - oral	Zydelig	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ifosfamide	Ifex, Mitoxana	J9208	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Imatinib - oral	Gleevec	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Imatinib - oral	Gleevec	S0088	Medical Oncology - CHEMO	Primary	ORAL	Y	
Imatinib Mesylate - oral	Imkeldi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Imetelstat	Rytelo	J0870	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Imlunestrant - oral	Inluriyo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Inavolisib - oral	Itovebi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Inotuzumab Ozogamicin	Besponsa	J9229	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Interferon, gamma-1b	Actimmune	J9216	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Ipilimumab	Yervoy	J9228	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Irinotecan	Camptosar	J9206	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Irinotecan Liposome	Onivyde	J9205	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Isatuximab-irfc	Sarclisa	J9227	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Ivosidenib - oral	Tibsovo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ixabepilone	Ixempra	J9207	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Ixazomib - oral	Ninlaro	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Lanreotide (Cipla) - J1932		J1932	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Lanreotide (J1930)	Somatuline Depot	J1930	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Lapatinib - oral	Tykerb	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Larotrectinib - oral	Vitrakvi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Lazertinib - oral	Lazcluze	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Lenalidomide - oral	Revlimid	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y: Brand Revlimid Only	
Lenvatinib - oral	Lenvima	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Leuprolide Acetate (J1950: 3.75mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J1950	Medical Oncology - CHEMO	Primary - LHRH	INJECTABLE	Y	
Leuprolide Acetate (J1954: 7.5mg)	Lutrate Depot	J1954	Medical Oncology - CHEMO	Primary - LHRH	INJECTABLE	Y	
Leuprolide Acetate (J9217: 7.5mg)	Eligard, Lupron Depot, Lupron, Leuprolide Acetate	J9217	Medical Oncology - CHEMO	Primary - LHRH	INJECTABLE	Y	
Leuprolide Acetate (J9218: 1mg)	Lupron	J9218	Medical Oncology - CHEMO	Primary - LHRH	INJECTABLE	Y	
Leuprolide Mesylate	Camcevi	J1952	Medical Oncology - CHEMO	Primary - LHRH	INJECTABLE	Y	
Leuprolide Mesylate	Camcevi ETM	J9003	Medical Oncology - CHEMO	Primary - LHRH	INJECTABLE	Y	
Levoleucovorin	Fusilev	J0641	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Levoleucovorin	Khapzory	J0642	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Linvoseltamab-gcpt	Lynozytic	J9601	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Liposome-encapsulated combination of Daunorubicin and Cytarabine	Vyxeos	J9153	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Lomustine - oral	Gleostine, CCNU	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Loncastuximab tesirine-lpyl	Zynlonta	J9359	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Lorlatinib - oral	Lorbrena	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Lurbinectedin	Zepzelca	J9223	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Luspatercept-aamt	Reblozyl	J0896	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Margetuximab-cmkb	Margenza	J9353	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Melphalan (apotex)	Ivra	J9249	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Melphalan (hepzato)	Hepzato	J9248	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Melphalan HCL - inj	Evomela	J9246	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Melphalan HCL - NOS inj	Alkeran	J9245	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Mercaptopurine - oral	Purixan	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	Drug brought in scope for client at client request, effective 7/1/26.
Midostaurin - oral	Rydapt	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Mirdametinib - oral	Gomekli	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Mirvetuximab Soravtansine-gynx	Elahere	J9063	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Mitomycin	Jelmyto	J9281	Medical Oncology - CHEMO	Primary	PYELOCALYCEAL	Y	Medicare Part B
Mitomycin	Mutamycin	J9280	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Mitomycin (intravesical solution)	Zusduri	J9282	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Mitoxantrone HCL	Novantrone	J9293	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Mobocertinib - oral	Exkivity	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Mogamulizumab-kpkc	Poteligeo	J9204	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Momelotinib - oral	Ojjaara	J8499	Medical Oncology - CHEMO	Primary	ORAL	Y	
Mosunetuzumab-axgb	Lunsumio	J9350	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Naxitamab-gqgk	Danyelza	J9348	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Necitumumab	Portrazza	J9295	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Nelarabine	Arranon	J9261	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Neratinib - oral	Nerlynx	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Netupitant/Palonosetron - oral	Akynzeo	J8655	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y	
Nilotinib d-tartrate - oral	Danziten	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Nilotinib HCL - oral	Tasigna	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Nilotinib Tartrate - oral	Danziten	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Nilutamide - oral	Nilandron	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Niraparib - oral	Zejula	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Niraparib and Abiraterone Acetate - Oral	Akeega	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Nirogacestat - oral	Ogsiveo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Nivolumab	Opdivo	J9299	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Nivolumab and Relatlimab-rmbw	Opdualag	J9298	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Nivolumab and Hyaluronidase-nvhy	Opdivo Qvantig	J9289	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Nogapendekin alfa inbakicept-pmln	Anktiva	J9028	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Obinutuzumab	Gazyva	J9301	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Octreotide, depot	Sandostatin LAR	J2353	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Octreotide, depot	Sandostatin LAR	J2353	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Octreotide, non-depot	Sandostatin	J2354	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Octreotide, non-depot	Sandostatin	J2354	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Ofatumumab	Arzerra	J9302	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Olaparib - oral	Lynparza	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Olutasidenib - oral	Rezlidhia	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Osimertinib - oral	Tagrisso	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Oxaliplatin	Eloxatin	J9263	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Paclitaxel	Nov-Onxol, Taxol	J9267	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Paclitaxel (albumin-bound)	Abraxane	J9264	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pacritinib - oral	Vonjo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Palbociclib - oral	Ibrance	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Panitumumab	Vectibix	J9303	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pazopanib - oral	Votrient	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Pegaspargase	Oncaspar	J9266	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pegfilgrastim, excludes biosimilar, 0.5 mg	Neulasta	J2506	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Pegfilgrastim-apgf	Nyvepria	Q5122	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Pegfilgrastim-bmez	Ziextenzo	Q5120	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Pegfilgrastim-cbqv	Udenyca	Q5111	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Pegfilgrastim-fpgk	Stimufend	Q5127	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Pegfilgrastim-jmdb	Fulphila	Q5108	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Pegfilgrastim-pbbk	Fylnetra	Q5130	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Pegfilgrastim-pccg	Ennumo	C9399	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	New biosimilar drug, effective 6/5/26.

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Pegfilgrastim-pccg	Ennumo	J3490	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	New biosimilar drug, effective 6/5/26.
Pegfilgrastim-pccg	Ennumo	J3590	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	New biosimilar drug, effective 6/5/26.
Pegfilgrastim-pccg	Ennumo	J9999	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	New biosimilar drug, effective 6/5/26.
Pegfilgrastim-unne	Armlupeg	Q5169	Medical Oncology - SPORT	Supportive	INJECTABLE	Y - 07/01/26	New biosimilar drug, effective 7/1/26; replacing NOC Codes J3590, J3490, C9399, J9999
Peginterferon, alfa-2a	Pegasys	J3590	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Peginterferon, alfa-2a	Pegasys	S0145	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pembrolizumab	Keytruda	J9271	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pembrolizumab and Berahyaluronidase alfa-pmph	Keytruda Qlex	J9277	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemetrexed	Alimta, Pemetrexed not otherwise specified	J9305	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemetrexed	Pemfexy	J9304	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemetrexed (accord)	Pemetrexed (accord)	J9296	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemetrexed (avyxa)	Axtle	J9292	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemetrexed (bluepoint)	Pemetrexed (bluepoint)	J9322	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemetrexed (pemrydi rtu)	PEMRYDI RTU	J9324	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemetrexed (pfizer / hospira)	Pemetrexed (pfizer / hospira)	J9294	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemetrexed (sandoz)	Pemetrexed (sandoz)	J9297	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemetrexed (teva)	Pemetrexed (teva)	J9314	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pemigatinib - oral	Pemazyre	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Penpulimab-kcqx		C9399	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Penpulimab-kcqx		J3490	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Penpulimab-kcqx		J3590	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Penpulimab-kcqx		J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pentostatin	Nipent	J9268	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pertuzumab	Perjeta	J9306	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pertuzumab / trastuzumab / hyaluronidase-zzxf	Phesgo	J9316	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pexidartinib - oral	Turalio	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Pirtobrutinib - oral	Jaypirca	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Pivekimab sunirine-pvzy	Decnupaz	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	New Drug, effective 6/5/26.

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Pivekimab sunirine-pvzy	Decnupaz	J3490	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	New Drug, effective 6/5/26.
Pivekimab sunirine-pvzy	Decnupaz	J3590	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	New Drug, effective 6/5/26.
Pivekimab sunirine-pvzy	Decnupaz	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	New Drug, effective 6/5/26.
Polatuzumab vedotin-piiq	Polivy	J9309	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pomalidomide - oral	Pomalyst	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ponatinib - oral	Iclusig	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Pralatrexate	Folotyng	J9307	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Pralsetinib - oral	Gavreto	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Quizartinib - oral	Vanflyta	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ramucirumab	Cyramza	J9308	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Regorafenib - oral	Stivarga	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Relacorilant - oral	Lifyorli	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	New oral drug add
Relugolix - oral	Orgovyx	J8999	Medical Oncology - CHEMO	Primary - LHRH	ORAL	Y	
Repotrectinib - oral	Augtyro	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Retifanlimab-dlwr	Zynyz	J9345	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Revumenib - oral	Revuforj	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ribociclib - oral	Kisqali	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ribociclib Tablets / Letrozole Tablets - Oral	Kisqali Femara Co-Pack	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ripretinib - oral	Qinlock	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Rituximab	Rituxan	J9312	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Rituximab and Hyaluronidase Human	Rituxan Hycela	J9311	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Rituximab-abbs	Truxima	Q5115	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Rituximab-arrx	Riabni	Q5123	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Rituximab-pvvr	Ruxience	Q5119	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Rolapitant - oral	Varubi	J8670	Medical Oncology - SPORT	Supportive - Antiemetic	ORAL	Y	
Romidepsin (lyophilized)	Istodax	J9319	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Romidepsin (non-lyophilized)	Romidepsin (non-lyophilized)	J9318	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Romiplostim	Nplate	J2802	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Romiplostim	Nplate	J2802	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Ropeginterferon alfa-2b-njft	Besremi	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Ropeginterferon alfa-2b-njft	Besremi	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Rucaparib - oral	Rubraca	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ruxolitinib - oral	Jakafi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Sacituzumab govitecan-hziy	Trodelyv	J9317	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Selinexor - oral	Xpovio	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Selpercatinib - oral	Retevmo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Selumetinib - oral	Koselugo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Services provided as a part of a phase I clinical trial	Clinical Trial Phase 1	S9988	Medical Oncology - CHEMO	Primary	Varies per trial	Y	
Services provided as a part of a phase II clinical trial	Clinical Trial Phase 2	S9990	Medical Oncology - CHEMO	Primary	Varies per trial	Y	
Services provided as a part of a phase III clinical trial	Clinical Trial Phase 3	S9991	Medical Oncology - CHEMO	Primary	Varies per trial	Y	
Sevabertinib - oral	Hyrnuo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Siltuximab	Sylvant	J2860	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Sipuleucel-T	Provenge	Q2043	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Sirolimus protein-bound particles for injectable suspension (albumin bound)	Fyarro	J9331	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Sodium Thiosulfate Injection	Pedmark	J0208	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Sodium Thiosulfate injection (hope)	Sodium Thiosulfate injection (hope)	J0209	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Sonidegib - oral	Odomzo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Sonrotoclax - oral	Beqalzi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	New Drug, effective 6/5/26.
Sorafenib Tosylate - oral	Nexavar	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Sotorasib - oral	Lumakras	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Streptozocin	Zanosar	J9320	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Sunitinib - oral	Sutent	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Sunvozertinib - oral	Zegfrovy	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Tafasitamab-cxix	Monjuvi	J9349	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Tagraxofusp-erzs	Elzonris	J9269	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Talazoparib - oral	Talzenna	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Taletrectinib - oral	Ibtrozi	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Talimogene Laherparepvec	Imlygic	J9325	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Talquetamab-tgvs	Talvey	J3055	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Tarlatamab-dlle	Imdelltra	J9026	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Tazemetostat - oral	Tazverik	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Tbo-filgrastim	Granix	J1447	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Tebentafusp-tebn	Kimtrak	J9274	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Teclistamab-cqyv	Tecvayli	J9380	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Telisotuzumab vedotin-tllv	Emrelis	J9326	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Telotristat ethyl - oral	Xermelo	J8499	Medical Oncology - CHEMO	Primary	ORAL	Y	
Temozolomide - inj	Temodar	J9328	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Temozolomide - oral	Temodar	J8700	Medical Oncology - CHEMO	Primary	ORAL	Y	Medicare Part B
Temsirolimus	Torisel	J9330	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Tepotinib - oral	Tepmetko	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Thalidomide - oral	Thalomid	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Thiotepa	Tepylute	J9341	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Thiotepa Injection, not otherwise specified	Thiotepa Injection, not otherwise specified	J9342	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Tislelizumab-jsgr	Tevimbra	J9329	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Tisotumab vedotin-tftv	Tivdak	J9273	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Tivozanib - oral	Fotivda	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Tocilizumab	Actemra	J3262	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Tocilizumab	Actemra	J3262	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Tocilizumab-aazg	Tyenne	Q5135	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Tocilizumab-aazg	Tyenne	Q5135	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Tocilizumab-anoh	Avtozma	Q5156	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Tocilizumab-anoh	Avtozma	Q5156	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Tocilizumab-bavi	Tofidence	Q5133	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Tocilizumab-bavi	Tofidence	Q5133	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Topotecan - inj	Hycamtin	J9351	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Topotecan - oral	Hycamtin	J8705	Medical Oncology - CHEMO	Primary	ORAL	Y	Medicare Part B
Toripalimab-tpzi	Loqtorzi	J3263	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Tovorafenib - oral	Ojemda	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Trabectedin	Evid	C9399	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Trabectedin	Evid	J9999	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Trabectedin	Yondelis	J9352	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Trametinib - oral	Mekinist	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Trastuzumab	Herceptin	J9355	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Trastuzumab and hyaluronidase-oysk	Herceptin Hylecta	J9356	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Trastuzumab-anns	Kanjinti	Q5117	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Trastuzumab-dkst	Ogivri	Q5114	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Trastuzumab-dttb	Ontruzant	Q5112	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Trastuzumab-pkrb	Herzuma	Q5113	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Trastuzumab-qyyp	Trazimera	Q5116	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Trastuzumab-strf	Hercessi	Q5146	Medical Oncology - CHEMO	Primary - Biosimilar	INJECTABLE	Y	
Tremelimumab-actl	Imjudo	J9347	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Trifluridine/Tipiracil - oral	Lonsurf	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Trilaciclib	Cosela	J1448	Medical Oncology - SPORT	Supportive	INJECTABLE	Y	
Triptorelin Pamoate	Trelstar	J3315	Medical Oncology - CHEMO	Primary - LHRH	INJECTABLE	Y	
Tucatinib - oral	Tukysa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Vandetanib - oral	Caprelsa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Vemurafenib - oral	Zelboraf	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Venetoclax - oral	Venclexta	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Vepdegestrant - oral	Veppanu	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	New Drug, effective 6/5/26.
Vimseltinib - oral	Romvimza	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Vinblastine Sulfate	Velban	J9360	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Vincristine Sulfate	Oncovin, Vincasar PFS	J9370	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	

Effective Date: 07/01/2026

Description	Alt Descriptions	Primary	Program	Drug Class	Administration Technique	Cigna Commercial	Drug Comments
Vinorelbine Tartrate	Navelbine	J9390	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Vismodegib - oral	Erivedge	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Vorasidenib - oral	Voranigo	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Vorinostat - oral	Zolanza	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Zanidatamab-hrii	Ziihera	J9276	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Zanubrutinib - oral	Brukinsa	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Zenocutuzumab-zbco	Bizengri	J9382	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Ziftomenib - oral	Komzifti	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	
Ziv-Aflibercept	Zaltrap	J9400	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Zolbetuximab-clzb	Vyloy	J1326	Medical Oncology - CHEMO	Primary	INJECTABLE	Y	
Zongertinib - oral	Hernexeos	J8999	Medical Oncology - CHEMO	Primary	ORAL	Y	